 |
Prospector
Profile
08.0015
|
| |
| Pharmaxis Ltd. |
NAICS |
541710 |
| 10 Rodborough Road
Frenchs Forest, New South Wales, Australia 2086 |
Description |
Biotechnology |
| 61-2-9451-5961 |
Employees |
68 |
| http://www.pharmaxis.com.au/ |
Revenue |
AUD(mil) |
0.1560 |
| |
Income |
AUD(mil) |
-24.1600 |
| |
Assets |
AUD(mil) |
82.6420 |
| |
Liability |
AUD(mil) |
6.0830 |
| |
(for the year ended 2007-06-30) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Pharmaxis Ltd. had a net loss pf AUD24.18 million for the year ended June 30, 2007, much higher than the net losses of AUD17.73 million and AUD10.45 million reported during the years ended June 30, 2006 and 2005, respectively. The Company reported revenues of AUD205,000 for the fiscal year ended June 30, 2007, compared to AUD6,000 in 2006 and none in 2005. As a result of its recurring losses, the Company's balance sheet at June 30, 2007, showed an accumulated deficit of AUD62.78 million.
|
| |
|
Intellectual Property:
As of October 31 2007, the Company owned or had exclusive rights to 18 issued U.S. and foreign patents and 11 pending U.S. and foreign patent applications. Of these, 9 issued patents and 3 pending applications relate to Aridol and Bronchitol. A pending application relates to PXS25 and PXS64 and has now entered the national phase. The remaining patents and applications relate to other aspects of its technology or other drug discovery programs that have not yet entered a full development program. The Company has the exclusive worldwide rights from Sydney South West Area Health Service for certain key intellectual property and patents relating to the use of respirable dry powders for the assessment of bronchial hyper-responsiveness, a condition consistent with active asthma, for monitoring steroid use in asthma patients, and enhancing mucus clearance in diseases such as cystic fibrosis, bronchiectasis and chronic bronchitis. It also has an exclusive worldwide license from ANU Enterprises Pty Ltd. to develop and commercialize intellectual property relating to the treatment of inflammatory or immune-mediated conditions in patients by administering a phosphosugar. [SEC Filing 20-F 11-27-07]
|
| |
|
Description:
Pharmaxis engages in the research, development, and commercialization of human therapeutic products for the diagnosis and treatment of chronic respiratory and inflammatory/autoimmune diseases primarily in Australia.
|
| |
|
Officers:
Denis M. Hanley (Chair); Alan D. Robertson (CEO & Managing Dir.); Brett Charlton (Medical Director); John F. Crapper (COO); Ian A. McDonald (Chief Scientific Officer); David M. McGarvey (Sec. & CFO); Peter C. Farrell (Dir.); Charles P.H. Kiefel (Dir.); Malcolm J. McComas (Dir.); John Villiger (Dir.)
|
| |
|
Auditor:
WHB Seaton
|
| |
|
Securities:
Common Stock-Symbol PXSL; Nasdaq;
177,949,217 common shares outstanding as of June 30, 2007.
|
| |
| |
| |
| return to main page |
|
|
